CCCA, or central centrifugal cicatricial alopecia, is a type of scarring hair loss that starts at the crown of the scalp and gradually spreads outward in a circular pattern. Unlike temporary hair loss, CCCA destroys hair follicles and replaces them with scar tissue, making the hair loss permanent in affected areas. It primarily affects Black women, with a prevalence of 2.7% to 5.6% in this population, making it one of the most common forms of scarring alopecia.
How CCCA Damages Hair Follicles
Healthy hair follicles have a protective inner lining called the inner root sheath. In CCCA, this lining breaks down too early, leaving the follicle exposed. Once the barrier is compromised, chemicals, bacteria, and even the hair shaft itself can irritate surrounding tissue and trigger inflammation. This low-grade, ongoing inflammation slowly scars the follicle from the inside out.
As the condition progresses, the tissue that produces hair gets destroyed and replaced by connective (scar) tissue. Nearby follicles can fuse together at the surface, creating what dermatologists call “tufting,” where multiple hairs appear to emerge from a single opening. Once a follicle is fully scarred over, it can no longer produce hair.
Genetics Play a Role
A 2019 study published in the New England Journal of Medicine identified mutations in a gene called PADI3 that are associated with CCCA. This gene provides instructions for making an enzyme critical to proper hair shaft formation. In the initial group of 16 patients studied, 31% carried a PADI3 mutation, and the link held up in a larger replication group. The mutations cause the enzyme to misfold, reducing its activity and disrupting normal hair structure.
These genetic variants were significantly more common in patients with CCCA than in a control group of women of African ancestry. However, genetics alone don’t fully explain the condition. Researchers believe that the naturally more fragile structure of tightly coiled hair, combined with hereditary factors and grooming practices, likely work together to increase susceptibility.
Early Symptoms to Recognize
CCCA often starts subtly, and many people don’t notice it until the hair loss becomes visible. The earliest signs tend to be sensory rather than visual. In one clinical study, 80% of patients reported itching at the crown of the scalp, and the same percentage reported tenderness in that area. Hair breakage was reported by 70% of patients both at and beyond the crown. These symptoms can precede noticeable thinning by months or even years.
When a dermatologist examines the scalp with a magnifying tool called a dermatoscope, several telltale signs appear. The most common is a white or gray halo surrounding individual hair follicles, seen in 95% of patients. Redness around or between follicles shows up in about 82% of cases, and a honeycomb-like pattern on the scalp surface appears in 80%. Importantly, these changes can extend beyond the visibly affected area. Biopsies taken from scalp regions that looked normal under the naked eye still showed early scarring and inflammation under the microscope.
How CCCA Is Diagnosed
Diagnosis typically involves a combination of clinical examination, dermatoscopy, and a small scalp biopsy. The biopsy is important because CCCA can look similar to other types of hair loss in its early stages. Under the microscope, dermatologists look for specific signs: scarring around and between follicles, inflammatory cells clustered near the hair roots, and fragments of hair shaft trapped in scarred tissue. In later stages, the complete replacement of follicular tissue with scar tissue confirms the diagnosis.
Treatment Options
There is no cure for CCCA, but treatment can slow or stop the progression and reduce symptoms like itching and tenderness. The primary goal is to calm the inflammation before more follicles are permanently damaged.
First-line treatment typically involves potent topical corticosteroids applied directly to the affected scalp, sometimes combined with oral antibiotics that have anti-inflammatory properties. The American Academy of Dermatology also recommends dandruff shampoo if scaling is present, as this helps manage surface-level irritation. Topical minoxidil is sometimes used alongside corticosteroids to support any remaining active follicles.
Healthy hair care practices are considered an essential part of managing CCCA. While a direct causal link between specific hairstyles and developing CCCA hasn’t been proven, dermatologists recommend wearing loose rather than tight styles, avoiding hairstyles that irritate the scalp or cause breakage, and minimizing chemical processing. These steps help reduce additional inflammation and prevent overlapping hair loss from traction alopecia.
Can Lost Hair Grow Back?
Once a follicle is fully scarred, it cannot regrow hair. This is what makes early detection so important. Treatment can preserve the follicles that are still active and, in some cases, lead to modest improvements in hair density. One case study documented mild increases in follicular density during monthly platelet-rich plasma (PRP) treatments, but the gains were lost when treatments were spaced out to every six months. This suggests that ongoing, consistent treatment is necessary to maintain any improvements.
Stabilization, meaning the hair loss stops spreading, is a realistic and common treatment goal. One documented case achieved stabilization after two years of treatment, followed by a maintenance regimen of topical corticosteroids and minoxidil several times per week.
Hair Transplantation After Stabilization
For people whose CCCA has been inactive for an extended period, hair transplantation is a potential option, though outcomes are more modest than in non-scarring hair loss. Most providers recommend that the disease remain clinically stable for at least 12 to 24 months before considering a transplant. A biopsy is generally taken beforehand to confirm that inflammation has truly subsided.
Graft survival in CCCA patients sits around 60%, compared to over 90% in people with non-scarring hair loss. Results are variable, and success depends heavily on sustained disease control both before and after the procedure. A flare of inflammation after transplantation can destroy the newly placed grafts, so careful patient selection is critical.